Frankfurt
30.12.24
08:19 Uhr
0,164 Euro
-0,010
-5,48 %
-5,48 %
Chart-Typ:
Zeitraum:
| Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen |
| Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen |
| Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025... ► Artikel lesen |
| Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen |
| Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen |
| Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen |
| Tempus AI, Inc.: Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024 | Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the... ► Artikel lesen |
| Tempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology Pipeline | BERLIN (dpa-AFX) - Tempus AI, Inc (TEM), a technology company using AI to advance precision medicine and patient care, Wednesday announced a multi-year real world data collaboration with BioNTech... ► Artikel lesen |
| Opening Bell: Coca-Cola, Visa, PayPal, Netflix, VF Corp, Philip Morris, Tempus AI | Die kleine Zinseuphorie der letzten Woche ist an der Wall Street zum Wochenauftakt etwas in den Hintergrund gerückt. Der Dow Jones gab 0,16 Prozent ab. Der Nasdaq 100 verlor 1,04 Prozent. Bei den Einzelthemen... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COMBIGENE AB finden Sie auf Wallstreet Online.
